公开(公告)号：US10246413B2

公开(公告)日：2019-04-02

申请号：US15703056

申请日：2017-09-13

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： Steffen Gaali ,  Felix Hausch ,  Alexander Kirschner ,  Xixi Feng ,  Andreas Bracher ,  Gerd Ruehter

IPC分类号： C07D233/44 ,  A61K31/415 ,  C07D405/12 ,  C07D207/16 ,  C07D401/14 ,  C07D401/12 ,  C07D279/12 ,  C07D211/60 ,  C07D211/78 ,  C12N9/90 ,  G06F19/16 ,  C07K5/078

摘要： The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

公开(公告)号：US20180072667A1

公开(公告)日：2018-03-15

申请号：US15703056

申请日：2017-09-13

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： Steffen Gaali ,  Felix Hausch ,  Alexander Kirschner ,  Xixi Feng ,  Andreas Bracher ,  Gerd Ruehter

IPC分类号： C07D207/16 ,  G06F19/16 ,  C12N9/90 ,  C07D211/78 ,  C07D401/14 ,  C07D279/12 ,  C07D405/12 ,  C07D401/12 ,  C07D211/60

CPC分类号： C07D207/16 ,  C07B2200/13 ,  C07D211/60 ,  C07D211/78 ,  C07D279/12 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07K5/06139 ,  C12N9/90 ,  C12Y502/01008 ,  G06F19/16

摘要： The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

公开(公告)号：US09845292B2

公开(公告)日：2017-12-19

申请号：US15023095

申请日：2014-09-15

申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： Steffen Gaali ,  Felix Hausch ,  Alexander Kirschner ,  Xixi Feng ,  Andreas Bracher ,  Gerd Ruehter

IPC分类号： C07D211/06 ,  C07D295/00 ,  C07D207/16 ,  C07D401/14 ,  C07D401/12 ,  C07D405/12 ,  C07D279/12 ,  C07D211/60 ,  C07D211/78 ,  C12N9/90 ,  G06F19/16

CPC分类号： C07D207/16 ,  C07B2200/13 ,  C07D211/60 ,  C07D211/78 ,  C07D279/12 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07K5/06139 ,  C12N9/90 ,  C12Y502/01008 ,  G06F19/16

摘要： The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.